Information Provided By:
Fly News Breaks for June 6, 2019
IFRX, CCXI
Jun 6, 2019 | 08:28 EDT
Raymond James analyst Steven Seedhouse removed hidradenitis suppurativa from his model for ChemoCentryx (CCXI) after InflaRx (IFRX) reported that its Phase IIb trial for C5a antibody IFX-1 failed, leading him to lower his price target on the shares to $17 from $24. However, he keeps a Strong Buy rating on ChemoCentryx shares and said he would be a buyer amid the weakness, citing Phase 2 data for avacopan in AAV and a near-term Phase 3 data readout for AAV in Q4.
News For CCXI;IFRX From the Last 2 Days
There are no results for your query CCXI;IFRX